|
1
|
Sanchez E, Li M, Kitto A, Li J, Wang CS,
Kirk DT, Yellin O, Nichols CM, Dreyer MP, Ahles CP, et al: Serum
B-cell maturation antigen is elevated in multiple myeloma and
correlates with disease status and survival. Br J Haematol.
158:727–738. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fragioudaki M, Boula A, Tsirakis G,
Psarakis F, Spanoudakis M, Papadakis IS, Pappa CA and Alexandrakis
MG: B cell-activating factor: its clinical significance in multiple
myeloma patients. Ann Hematol. 91:1413–1418. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tsukada Y, Hattori Y, Nakajima H, Yokoyama
K, Murata M, Shimizu N, Kondo N and Okamoto S: B-cell acute
lymphoblastic leukemia developed 5 years after autologous stem cell
transplantation for multiple myeloma. Rinsho Ketsueki. 53:219–223.
2012.(In Japanese). PubMed/NCBI
|
|
4
|
Jöhrer K, Hofbauer SW, Zelle-Rieser C,
Greil R and Hartmann TN: Chemokine-dependent B cell-T cell
interactions in chronic lymphocytic leukemia and multiple myeloma -
targets for therapeutic intervention? Expert Opin Biol Ther.
12:425–441. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kurzrock R, Voorhees PM, Casper C, Furman
RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani SZ,
et al: A phase I, open-label study of siltuximab, an anti-IL-6
monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma,
multiple myeloma, or Castleman disease. Clin Cancer Res.
19:3659–3670. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Reijmers RM, Spaargaren M and Pals ST:
Heparan sulfate proteoglycans in the control of B cell development
and the pathogenesis of multiple myeloma. FEBS J. 280:2180–2193.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang SM, Zhang TL, Jiang YM, Wu HY, Hao LM
and Xing XH: Expression and significance of B cell-activating
factor of TNF family (BAFF) and B cell lymphoma/leukemia-2 (BCL-2)
in multiple myeloma. Zhongguo Shi Yan Xue Ye Xue Za Zhi.
19:395–398. 2011.(In Chinese). PubMed/NCBI
|
|
8
|
Carpenter RO, Evbuomwan MO, Pittaluga S,
Rose JJ, Raffeld M, Yang S, Gress RE, Hakim FT and Kochenderfer JN:
B-cell maturation antigen is a promising target for adoptive T-cell
therapy of multiple myeloma. Clin Cancer Res. 19:2048–2060. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Boucher K, Parquet N, Widen R, Shain K,
Baz R, Alsina M, Koomen J, Anasetti C, Dalton W and Perez LE:
Stemness of B-cell progenitors in multiple myeloma bone marrow.
Clin Cancer Res. 18:6155–6168. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Goel A, Spitz DR and Weiner GJ:
Manipulation of cellular redox parameters for improving therapeutic
responses in B-cell lymphoma and multiple myeloma. J Cell Biochem.
113:419–425. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mahtouk K, Tjin EP, Spaargaren M and Pals
ST: The HGF/MET pathway as target for the treatment of multiple
myeloma and B-cell lymphomas. Biochim Biophys Acta. 1806:208–219.
2010.PubMed/NCBI
|
|
12
|
Hollander N: Current vaccination
strategies for the treatment of B-cell lymphoma and multiple
myeloma. Crit Rev Immunol. 29:399–418. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen P, Li B, Zhuang W, Huang H, Zhang H
and Fu J: Multiple bone lesions and hypercalcemia presented in
diffuse large B cell lymphoma: mimicking multiple myeloma? Int J
Hematol. 91:716–722. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Harding SJ, Mead GP, Bradwell AR and
Berard AM: Serum free light chain immunoassay as an adjunct to
serum protein electrophoresis and immunofixation electrophoresis in
the detection of multiple myeloma and other B-cell malignancies.
Clin Chem Lab Med. 47:302–304. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Srinivasan S and Schiffer CA: Concurrent
B-cell chronic lymphocytic leukemia and multiple myeloma treated
successfully with lenalidomide. Leuk Res. 33:561–564. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ilić V, Milosević-Jovcić N, Petrović S,
Marković D, Stefanović G and Ristić T: Glycosylation of IgG B cell
receptor (IgG BCR) in multiple myeloma: relationship between
sialylation and the signal activity of IgG BCR. Glycoconj J.
25:383–392. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fragioudaki M, Tsirakis G, Pappa CA,
Aristeidou I, Tsioutis C, Alegakis A, Kyriakou DS, Stathopoulos EN
and Alexandrakis MG: Serum BAFF levels are related to angiogenesis
and prognosis in patients with multiple myeloma. Leuk Res.
36:1004–1008. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shen X, Zhang X, Xu G and Ju S: BAFF-R
gene induced by IFN-γ in multiple myeloma cells is related to NF-κB
signals. Cell Biochem Funct. 29:513–520. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shen X, Zhu W, Zhang X, Xu G and Ju S: A
role of both NF-κB pathways in expression and transcription
regulation of BAFF-R gene in multiple myeloma cells. Mol Cell
Biochem. 357:21–30. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li LS, Shen JK and Zhang GS: Effect of
BAFF/APRIL mRNA expression induced by glucocorticoid and bortezomib
in multiple myeloma cells in vitro. Zhongguo Shi Yan Xue Ye Xue Za
Zhi. 19:1419–1423. 2011.(In Chinese). PubMed/NCBI
|
|
21
|
Quinn J, Glassford J, Percy L, Munson P,
Marafioti T, Rodriguez-Justo M and Yong K: APRIL promotes
cell-cycle progression in primary multiple myeloma cells: influence
of D-type cyclin group and translocation status. Blood.
117:890–901. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Moreaux J, Sprynski AC, Dillon SR, Mahtouk
K, Jourdan M, Ythier A, Moine P, Robert N, Jourdan E, Rossi JF, et
al: APRIL and TACI interact with syndecan-1 on the surface of
multiple myeloma cells to form an essential survival loop. Eur J
Haematol. 83:119–129. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ho J, Yang L, Banihashemi B, Martin L,
Halpenny M, Atkins H, Sabloff M, McDiarmid SA, Huebsch LB,
Bence-Bruckler I, et al: Contaminating tumour cells in autologous
PBSC grafts do not influence survival or relapse following
transplant for multiple myeloma or B-cell non-Hodgkin's lymphoma.
Bone Marrow Transplant. 43:223–228. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Peh SC, Gan GG, Lee LK and Eow GI:
Clinical relevance of CD10, BCL-6 and multiple myeloma-1 expression
in diffuse large B-cell lymphomas in Malaysia. Pathol Int.
58:572–579. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ianotto JC, Tempescul A, Eveillard JR,
Marion V, Quintin-Roué I and Berthou C: Tri-lineage disease
involving sideroblastic anaemia, multiple myeloma and B-cell
non-Hodgkin's lymphoma in the same patient. Ann Hematol.
88:273–274. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kuiper R, Broyl A, de Knegt Y, van Vliet
MH, van Beers EH, van der Holt B, el Jarari L, Mulligan G, Gregory
W, Morgan G, et al: A gene expression signature for high-risk
multiple myeloma. Leukemia. 26:2406–2413. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Novak AJ, Grote DM, Ziesmer SC, Rajkumar
V, Doyle SE and Ansell SM: A role for IFN-lambda1 in multiple
myeloma B cell growth. Leukemia. 22:2240–2246. 2008. View Article : Google Scholar : PubMed/NCBI
|
